Market Price

18.25 

-0.18 2.5%

as of May 24 '19

52 Week Range:

16.69 23.98


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

Takara Bio Inc., together with its subsidiaries, operates as a biotechnology company in Japan and internationally. It operates through Bioindustry, Gene Therapy, and AgriBio segments. The company develops original research reagents and scientific instruments; and provides contracted services that utilize new genetic engineering and cell engineering technologies on consistent basis, which support life sciences field that range from basic research to drug discovery and development. Its contracted services include development of virus vectors and cells for gene transduction based on good gene, cellular and tissue-based product manufacturing practices, and good manufacturing practices; quality and safety testing services; and production and storage of cell banks. The company also provides a package of regenerative medicine development and genetic testing support services, such as genetic analysis. In addition, it engages in the development and commercialization of various gene therapies, including oncolytic virus Canerpaturev for strain of the herpes simplex virus, which exhibits antitumor activity when inserted into a cancerous region; siTCR gene therapy, which is in Phase I/II clinical trials for the treatment of esophageal cancer, synovial sarcoma, and other cancers; and CD19 chimeric antigen receptors gene therapy for the treatment of adult acute lymphocytic leukemia. Further, the company provides functional foods, such as Gagome kombu (kelp) fucoidan, Peucedanum japonicum-derived isosamidin, Dioscorea esculenta-derived Yamsgenin, and mushroom products. Additionally, it produces various mushroom types, such as Honshimeji, Hatakeshimeji, and Bunashimeji. The company was founded in 2002 and is headquartered in Kusatsu, Japan. Takara Bio Inc. is a subsidiary of Takara Holdings Inc.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Mar '09 Mar '10 Mar '11 Mar '12 Mar '13 Mar '14 Mar '15 Mar '16 Mar '17 Mar '18 Mar '19
Equity (BVPS) 2.51
2.68
2.84
3.04
2.86
3.23
3.66
3.88
4.05
3.80
growth rate 6.8% 6.0% 7.0% -5.9% 12.9% 13.3% 6.0% 4.4% -6.2%
Earnings BIT 1,955.00
2,303.00
2,669.00
3,204.00
3,556.00
5,465.00
growth rate 17.8% 15.9% 20.0% 11.0% 53.7%
Avg.PE 75.89
119.60
107.13
74.73
growth rate 57.6% -10.4% -30.2%
ROA 1.45
1.36
1.40
2.36
3.22
2.69
1.49
2.01
2.02
3.43
growth rate -6.2% 2.9% 68.6% 36.4% -16.5% -44.6% 34.9% 0.5% 69.8%
ROE 1.69
1.58
1.60
2.69
3.67
2.99
1.65
2.23
2.26
3.84
growth rate -6.5% 1.3% 68.1% 36.4% -18.5% -44.8% 35.2% 1.4% 69.9%
ROIC 1.34
1.32
1.45
2.50
3.47
2.81
1.55
2.09
2.16
3.77
growth rate -1.5% 9.9% 72.4% 38.8% -19.0% -44.8% 34.8% 3.4% 74.5%
Cur. Ratio 6.78
7.06
8.82
7.79
7.83
9.56
6.70
7.76
7.30
6.10
growth rate 4.1% 24.9% -11.7% 0.5% 22.1% -29.9% 15.8% -5.9% -16.4%
Quick Ratio 5.62
5.98
7.64
6.77
6.73
8.28
5.63
6.62
6.23
4.80
growth rate 6.4% 27.8% -11.4% -0.6% 23.0% -32.0% 17.6% -5.9% -23.0%
Leverage 1.16
1.15
1.13
1.15
1.13
1.10
1.12
1.11
1.12
1.11
growth rate -0.9% -1.7% 1.8% -1.7% -2.7% 1.8% -0.9% 0.9% -0.9%
Balance Sheet Mar '09 Mar '10 Mar '11 Mar '12 Mar '13 Mar '14 Mar '15 Mar '16 Mar '17 Mar '18 Mar '19
Acct.Receivable 5,951.00
6,523.00
7,212.00
6,789.00
7,425.00
7,989.00
8,563.00
growth rate 9.6% 10.6% -5.9% 9.4% 7.6% 7.2%
Acct.Payable 1,605.00
1,551.00
1,939.00
1,690.00
1,944.00
1,875.00
1,536.00
growth rate -3.4% 25.0% -12.8% 15.0% -3.6% -18.1%
Cur.Assets 31,138.00
41,817.00
36,447.00
42,158.00
43,964.00
35,032.00
35,275.00
growth rate 34.3% -12.8% 15.7% 4.3% -20.3% 0.7%
Total Assets 46,649.00
62,500.00
66,425.00
66,591.00
67,143.00
68,854.00
71,040.00
growth rate 34.0% 6.3% 0.3% 0.8% 2.6% 3.2%
Cash 18,267.00
6,430.00
7,071.00
19,384.00
28,078.00
17,537.00
17,033.00
growth rate -64.8% 10.0% 174.1% 44.9% -37.5% -2.9%
Inventory 3,466.00
4,421.00
4,639.00
5,099.00
5,461.00
6,010.00
6,735.00
growth rate 27.6% 4.9% 9.9% 7.1% 10.1% 12.1%
Cur.Liabilities 3,977.00
4,372.00
5,439.00
5,430.00
6,025.00
5,745.00
6,017.00
growth rate 9.9% 24.4% -0.2% 11.0% -4.7% 4.7%
Liabilities 5,184.00
5,373.00
6,783.00
6,482.00
7,159.00
6,897.00
6,946.00
growth rate 3.7% 26.2% -4.4% 10.4% -3.7% 0.7%
LT Debt 273.00
228.00
179.00
130.00
82.00
growth rate -16.5% -21.5% -27.4% -36.9%
Equity 57,069.00
59,541.00
60,007.00
59,884.00
61,851.00
64,009.00
growth rate 4.3% 0.8% -0.2% 3.3% 3.5%
Common Shares 113.00
113.00
113.00
113.00
113.00
118.00
120.00
120.00
120.00
120.00
14,965.00
growth rate 0.0% 0.0% 0.0% 0.0% 4.4% 1.7% 0.0% 0.0% 0.0% 12,370.8%
Cash Flow Statement Mar '09 Mar '10 Mar '11 Mar '12 Mar '13 Mar '14 Mar '15 Mar '16 Mar '17 Mar '18 Mar '19
Capital Expenditures 2,341.00
5,713.00
4,891.00
2,263.00
1,443.00
1,499.00
5,977.00
growth rate 144.0% -14.4% -53.7% -36.2% 3.9% 298.7%
Cash Dividends 123.00
143.00
180.00
216.00
480.00
541.00
growth rate 16.3% 25.9% 20.0% 122.2% 12.7%
Cash From OA 2,226.00
2,251.00
3,558.00
3,021.00
3,584.00
3,935.00
5,783.00
growth rate 1.1% 58.1% -15.1% 18.6% 9.8% 47.0%
FCF per Share 0.08
0.13
0.07
0.16
-0.01
-0.10
-0.22
0.13
0.08
growth rate 62.5% -46.2% 128.6% -100.0% 0.0% 0.0% 100.0% -38.5%
Sale Purchase of Stock 11,464.00
growth rate
FCF 1,212.00
1,828.00
912.00
1,355.00
-277.00
-3,462.00
-1,333.00
647.00
2,067.00
2,343.00
-194.00
growth rate 50.8% -50.1% 48.6% -100.0% 0.0% 0.0% 100.0% 219.5% 13.4% -100.0%
Income Statement Mar '09 Mar '10 Mar '11 Mar '12 Mar '13 Mar '14 Mar '15 Mar '16 Mar '17 Mar '18 Mar '19
Sales 20,564.00
23,905.00
25,969.00
29,729.00
29,375.00
32,312.00
35,841.00
growth rate 16.3% 8.6% 14.5% -1.2% 10.0% 10.9%
Op.Income 1,459.00
1,955.00
2,303.00
2,669.00
3,204.00
3,556.00
5,465.00
growth rate 34.0% 17.8% 15.9% 20.0% 11.0% 53.7%
IBT 2,185.00
2,480.00
2,904.00
2,804.00
3,361.00
4,821.00
growth rate 13.5% 17.1% -3.4% 19.9% 43.4%
Net Income 1,459.00
1,470.00
963.00
1,334.00
1,352.00
2,335.00
3,657.00
growth rate 0.8% -34.5% 38.5% 1.4% 72.7% 56.6%
EPS 5.68
5.23
5.37
9.06
12.89
12.45
8.01
11.08
11.24
19.39
growth rate -7.9% 2.7% 68.7% 42.3% -3.4% -35.7% 38.3% 1.4% 72.5%
Gross Profit 11,024.00
12,574.00
13,827.00
16,324.00
16,953.00
18,655.00
20,686.00
growth rate 14.1% 10.0% 18.1% 3.9% 10.0% 10.9%
R&D 3,026.00
3,401.00
4,275.00
4,101.00
4,653.00
4,337.00
growth rate 12.4% 25.7% -4.1% 13.5% -6.8%

Quarterly Statements

Item Name Mar '18 Jun '18 Sep '18 Dec '18 Mar '19
Earnings BIT 1,946.00
1,545.00
1,079.00
810.00
2,031.00
growth rate -20.6% -30.2% -24.9% 150.7%
Balance Sheet Mar '18 Jun '18 Sep '18 Dec '18 Mar '19
Acct.Receivable 7,989.00
5,950.00
6,729.00
6,993.00
8,563.00
growth rate -25.5% 13.1% 3.9% 22.5%
Acct.Payable 1,875.00
1,623.00
1,555.00
2,120.00
1,536.00
growth rate -13.4% -4.2% 36.3% -27.6%
Cur.Assets 35,032.00
34,364.00
35,420.00
36,134.00
35,275.00
growth rate -1.9% 3.1% 2.0% -2.4%
Total Assets 68,854.00
67,643.00
68,677.00
70,705.00
71,040.00
growth rate -1.8% 1.5% 3.0% 0.5%
Cash 17,537.00
18,689.00
19,111.00
18,183.00
17,033.00
growth rate 6.6% 2.3% -4.9% -6.3%
Inventory 6,010.00
6,653.00
6,680.00
8,072.00
6,735.00
growth rate 10.7% 0.4% 20.8% -16.6%
Cur.Liabilities 5,745.00
5,743.00
5,442.00
6,567.00
6,017.00
growth rate 0.0% -5.2% 20.7% -8.4%
Liabilities 6,897.00
6,722.00
6,411.00
7,513.00
6,946.00
growth rate -2.5% -4.6% 17.2% -7.6%
LT Debt
growth rate
Equity 61,851.00
60,820.00
62,171.00
63,093.00
64,009.00
growth rate -1.7% 2.2% 1.5% 1.5%
Common Shares 14,965.00
14,965.00
14,965.00
14,965.00
14,965.00
growth rate 0.0% 0.0% 0.0% 0.0%
Cash Flow Statement Mar '18 Jun '18 Sep '18 Dec '18 Mar '19
Capital Expenditures 590.00
829.00
435.00
1,978.00
2,735.00
growth rate 40.5% -47.5% 354.7% 38.3%
Cash Dividends 508.00
508.00
32.00
1.00
growth rate 0.0% -93.7% -96.9%
Cash From OA 3,348.00
2,954.00
759.00
434.00
1,636.00
growth rate -11.8% -74.3% -42.8% 277.0%
FCF 2,758.00
2,125.00
324.00
-1,544.00
-1,099.00
growth rate -23.0% -84.8% -100.0% 0.0%
Income Statement Mar '18 Jun '18 Sep '18 Dec '18 Mar '19
Sales 9,666.00
8,847.00
8,523.00
8,518.00
9,953.00
growth rate -8.5% -3.7% -0.1% 16.9%
Op.Income 1,946.00
1,545.00
1,079.00
810.00
2,031.00
growth rate -20.6% -30.2% -24.9% 150.7%
IBT 1,620.00
1,548.00
888.00
267.00
2,118.00
growth rate -4.4% -42.6% -69.9% 693.3%
Net Income 1,267.00
1,032.00
688.00
368.00
1,569.00
growth rate -18.6% -33.3% -46.5% 326.4%
Gross Profit 5,888.00
5,356.00
4,965.00
4,620.00
5,745.00
growth rate -9.0% -7.3% -7.0% 24.4%
R&D 1,236.00
1,014.00
1,090.00
1,060.00
1,173.00
growth rate -18.0% 7.5% -2.8% 10.7%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

D (43.63)

YOY Growth Grade:

D (36.90)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

PE and EPS

Historical Current Forward
PE 74.73 64.49
EPS / Growth 0.28

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 2.6%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 2.6% 2.6% 2.6%
Future PE 0.01 2.65 2.65
Future EPS 0.37 0.37 0.37
Value Price
MOS %
0.00
-100.0%
0.24
-98.7%
0.24
-98.7%
MOS Price 0.00 0.12 0.12
IRT 37.52 37.52 37.52

Graham Number:

NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.